Who are Aclacur's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zelnorm, Mexitil, Forane, Amoxil, Nalidixate, Dihydroergocriptine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aclarubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Aclacur — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aclacur (ACLARUBICIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: aclarubicin. Area: Oncology.

phase 3 aclarubicin 5-hydroxytryptamine receptor 2B Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Aclacur (ACLARUBICIN). Aclacur works by binding to the 5-hydroxytryptamine receptor 2B, which is involved in cell growth and proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aclacur TARGET	ACLARUBICIN		phase 3	aclarubicin	5-hydroxytryptamine receptor 2B
Zelnorm	TEGASEROD		marketed	Serotonin-4 Receptor Agonist	5-hydroxytryptamine receptor 2B	2002-01-01
Mexitil	MEXILETINE	Boehringer Ingelheim	marketed	Antiarrhythmic	5-hydroxytryptamine receptor 2B	1985-01-01
Forane	ISOFLURANE	Baxter	marketed	General Anesthetic [EPC]	5-hydroxytryptamine receptor 2B	1979-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	marketed	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Nalidixate	NALIDIXIC ACID		marketed	nalidixic acid	5-hydroxytryptamine receptor 2B	1964-01-01
Dihydroergocriptine	dihydroergocryptine		marketed	dihydroergocryptine	5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 7

Recent regulatory actions (last 90 days)

2026-03-23 — Mexitil · FDA · approved · US · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-12-08 — Amoxil · 8778924 · Compound · US
2026-12-08 — Amoxil · 8357394 · Formulation · US
2027-05-07 — Amoxil · 8299052 · Method of Use · US

Sponsor landscape (aclarubicin class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aclacur — Competitive Intelligence Brief. https://druglandscape.com/ci/aclarubicin. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing